AR094791A1 - Composiciones y métodos para mejorar las respuestas inmunes ante una infección por eimeria o para limitar una infección por eimeria - Google Patents

Composiciones y métodos para mejorar las respuestas inmunes ante una infección por eimeria o para limitar una infección por eimeria

Info

Publication number
AR094791A1
AR094791A1 ARP140100470A ARP140100470A AR094791A1 AR 094791 A1 AR094791 A1 AR 094791A1 AR P140100470 A ARP140100470 A AR P140100470A AR P140100470 A ARP140100470 A AR P140100470A AR 094791 A1 AR094791 A1 AR 094791A1
Authority
AR
Argentina
Prior art keywords
eimeria infection
methods
compositions
limit
infection
Prior art date
Application number
ARP140100470A
Other languages
English (en)
Inventor
Shivaramaiah Srichaitanya
Barta John
Bielke Lisa
Berghman Luc
Hargis Billy
B Faulkner Olivia
Original Assignee
Univ Arkansas
Texas A & M Univ Sys
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Arkansas, Texas A & M Univ Sys filed Critical Univ Arkansas
Publication of AR094791A1 publication Critical patent/AR094791A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/002—Protozoa antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/002—Protozoa antigens
    • A61K39/012—Coccidia antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/002—Protozoa antigens
    • A61K39/015—Hemosporidia antigens, e.g. Plasmodium antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/44—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from protozoa
    • C07K14/445—Plasmodium
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/523—Bacterial cells; Fungal cells; Protozoal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/542—Mucosal route oral/gastrointestinal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55583—Polysaccharides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Vectores de vacuna y métodos de uso de los vectores de vacuna para mejorar la respuesta inmune contra un parásito Apicomplexa y reducir la morbilidad o la mortalidad asociadas con una subsiguiente infección. Los vectores de vacuna incluyen un polinucleótido que codifica un polipéptido romboide de Apicomplexa y opcionalmente incluyen un polipéptido inmunoestimulante expresado sobre la superficie del vector de vacuna.
ARP140100470A 2013-02-14 2014-02-14 Composiciones y métodos para mejorar las respuestas inmunes ante una infección por eimeria o para limitar una infección por eimeria AR094791A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201361764681P 2013-02-14 2013-02-14

Publications (1)

Publication Number Publication Date
AR094791A1 true AR094791A1 (es) 2015-08-26

Family

ID=51354559

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP140100470A AR094791A1 (es) 2013-02-14 2014-02-14 Composiciones y métodos para mejorar las respuestas inmunes ante una infección por eimeria o para limitar una infección por eimeria

Country Status (24)

Country Link
US (6) US9603915B2 (es)
EP (2) EP3610887B8 (es)
JP (2) JP6532407B2 (es)
KR (1) KR102228324B1 (es)
CN (2) CN111956796A (es)
AR (1) AR094791A1 (es)
AU (1) AU2014216246B2 (es)
BR (1) BR112015019283B1 (es)
CA (1) CA2900644C (es)
CL (1) CL2015002273A1 (es)
DK (1) DK2956165T3 (es)
EA (1) EA030929B1 (es)
ES (2) ES2758759T3 (es)
HK (1) HK1218880A1 (es)
HU (1) HUE047484T2 (es)
MX (1) MX2015010555A (es)
MY (1) MY173328A (es)
NZ (1) NZ711019A (es)
PH (1) PH12015501784A1 (es)
PL (1) PL2956165T3 (es)
PT (1) PT2956165T (es)
SG (2) SG10202109925TA (es)
WO (1) WO2014127185A1 (es)
ZA (1) ZA201505638B (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2214701T3 (en) * 2007-11-01 2016-12-12 Univ Arkansas CONFIGURATIONS AND METHODS FOR IMPROVING THE IMMUNE RESPONSES TO Eimeria
PT2956165T (pt) 2013-02-14 2019-11-29 Texas A & M Univ Sys Composições e métodos de potenciação das respostas imunitárias frente a eimeria ou limitação de uma infeção por eimeria
US10376571B2 (en) 2013-03-15 2019-08-13 The Board Of Trustees Of The University Of Arkansas Compositions and methods of enhancing immune responses to enteric pathogens
CN104940924B (zh) * 2015-05-29 2018-01-16 中国农业大学 一种球虫佐剂及其应用
EP3452069A4 (en) 2016-05-03 2020-02-12 The Board of Trustees of the University of Arkansas Yeast vaccine vector with immunostimulating and antigenic polypeptides and method for using them
CN106047914A (zh) * 2016-05-10 2016-10-26 吉林大学 一种用于预防猪弓形虫病的重组卡介苗及制备方法
CN110997912A (zh) * 2017-06-07 2020-04-10 星火治疗有限公司 用于改进的细胞转染和/或rAAV载体生产的增强剂
US11497801B2 (en) * 2021-02-19 2022-11-15 Sherryll Layton Compositions and methods of enhancing immune responses
CN115227810A (zh) * 2022-04-18 2022-10-25 福建农林大学 一种鸡抗巨型艾美耳球虫口服重组芽孢疫苗及其制备方法

Family Cites Families (92)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL170938B1 (pl) 1991-03-05 1997-02-28 Wellcome Found Sposób wytwarzania szczepionki przeciwko infekcjom Salmonella PL PL
US5961974A (en) 1991-10-25 1999-10-05 Immunex Corporation Monoclonal antibodies to CD40 ligand, pharmaceutical composition comprising the same and hybridomas producing the same
US5716805A (en) 1991-10-25 1998-02-10 Immunex Corporation Methods of preparing soluble, oligomeric proteins
US5981724A (en) 1991-10-25 1999-11-09 Immunex Corporation DNA encoding CD40 ligand, a cytokine that binds CD40
US5962406A (en) 1991-10-25 1999-10-05 Immunex Corporation Recombinant soluble CD40 ligand polypeptide and pharmaceutical composition containing the same
DK0897983T3 (da) 1991-10-25 2003-08-11 Immunex Corp Antistoffer mod CD40-L
US7405270B2 (en) 1991-10-25 2008-07-29 Immunex Corporation CD40-Ligand lacking native-pattern glycosylation
US5540926A (en) 1992-09-04 1996-07-30 Bristol-Myers Squibb Company Soluble and its use in B cell stimulation
EP0659086B1 (en) 1992-09-04 1998-11-11 The University of Saskatchewan Novel bacterial vaccines using vaccine strains of pathogenic bacteria
JP4242447B2 (ja) 1993-01-22 2009-03-25 イミュネックス・コーポレーション Ｃｄ４０リガンド遺伝子の突然変異の検出および治療
WO1995014487A1 (en) 1993-11-24 1995-06-01 The Australian National University Treatment of viral disease with cd40l peptide
ATE309267T1 (de) 1994-04-28 2005-11-15 Boehringer Ingelheim Pharma Methode zur proliferation und differenzierung von b-zellen und verwendungen dafür
KR19980702490A (ko) 1995-03-01 1998-07-15 스티븐 엘. 말라스카 면역 반응의 자극 방법
DE69631331T2 (de) 1995-06-07 2004-11-18 Immunex Corp., Seattle Cd40l mutein
US6479258B1 (en) 1995-12-07 2002-11-12 Diversa Corporation Non-stochastic generation of genetic vaccines
US6713279B1 (en) 1995-12-07 2004-03-30 Diversa Corporation Non-stochastic generation of genetic vaccines and enzymes
US6306387B1 (en) 1997-05-29 2001-10-23 The Research Foundation Of State University Of New York Antigen delivery system
US20030045492A1 (en) 1997-08-13 2003-03-06 Tang De-Chu C. Vaccination by topical application of recombinant vectors
US6969609B1 (en) 1998-12-09 2005-11-29 The United States Of America As Represented By The Department Of Health And Human Serivces Recombinant vector expressing multiple costimulatory molecules and uses thereof
CA2223225A1 (en) 1997-11-28 1999-05-28 Canadian Red Cross Society Method for inhibiting in vivo immune response
CA2313805A1 (en) 1997-12-19 1999-07-01 Immunex Corporation Method for reducing susceptibility to hiv infection
GB9806449D0 (en) 1998-03-25 1998-05-27 Peptide Therapeutics Ltd Attenuated bacteria useful in vaccines
US6190669B1 (en) 1998-05-13 2001-02-20 University Of Maryland, Baltimore Attenuated mutants of salmonella which constitutively express the Vi antigen
IT1299583B1 (it) 1998-05-19 2000-03-16 Vander Way Limited Uso di proteine hmg-i per la preparazione di medicamenti ad attivita' citotossica
DK1108034T3 (da) 1998-09-04 2008-11-10 Emergent Product Dev Uk Ltd Svækkede salmonella SPI2-mutanter som antigenbærere
US7300774B1 (en) 1999-12-09 2007-11-27 The Regents Of The University Of California Multimeric fusion proteins of the TNF superfamily ligands
CA2369820A1 (en) 1999-04-16 2000-10-26 Frank Dicker Nucleic acids encoding cd40/cd40l chimeric polypeptides, methods for their production and uses thereof
EP1067194A1 (en) 1999-04-16 2001-01-10 F. Hoffmann-La Roche Ag Vectors containing a gene coding for CD40 and/or CD40L under the control of a cytokine-inducible promoter which is a human acute phase amyloid A gene promoter. Methods for their production and uses thereof
US7803765B2 (en) 1999-05-05 2010-09-28 Phylogica Limited Methods of constructing biodiverse gene fragment libraries and biological modulators isolated therefrom
WO2001026608A2 (en) 1999-10-14 2001-04-19 Ledbetter Jeffrey A Dna vaccines encoding antigen linked to a domain that binds cd40
ATE269104T1 (de) 1999-12-28 2004-07-15 Akzo Nobel Nv Salmonella impfstoff, der keinen antikörper gegen flagellin oder gegen flagella induziert
DE60136334D1 (en) 2000-02-02 2008-12-11 Us Health Cd40-ligand als adjuvant für respiratorisches syncytialvirus-impfstoff
ATE300949T1 (de) 2000-03-17 2005-08-15 Pharmacia & Upjohn Co Llc Ssa inaktivierte salmonella impfstoffe
GB0015426D0 (en) 2000-06-24 2000-08-16 Univ Southampton Method for generating soluble highly multimeric proteins
WO2002000232A2 (en) 2000-06-26 2002-01-03 Maxygen, Inc. Methods and compositions for developing spore display systems for medicinal and industrial applications
WO2002036769A2 (en) 2000-10-31 2002-05-10 F. Hoffmann-La Roche Ag Nucleic acids encoding cd40/cd40l chimeric polypeptides, methods for their production and uses thereof
CN100447154C (zh) 2001-05-15 2008-12-31 费因斯坦医学研究学院 利用hmg片段作为抗炎症试剂
WO2002092773A2 (en) 2001-05-15 2002-11-21 Ortho-Mcneil Pharmaceutical, Inc. Ex-vivo priming for generating cytotoxic t lymphocytes specific for non-tumor antigens to treat autoimmune and allergic disease
US7220723B2 (en) 2001-05-15 2007-05-22 The Feinstein Institute For Medical Research Inhibitors of the interaction between HMGB polypeptides and toll-like receptor 2 as anti-inflammatory agents
IL159717A0 (en) 2001-07-06 2004-06-20 Biolog Lab Teva Ltd Nucleic acids encoding a recombinant 250 kda antigen from sporozoites/merozoites of eimeria maxima and their uses
ZA200400479B (en) 2001-07-06 2006-05-31 Abic Biolog Lab Teva Nucleic acids encoding recombinant 56 a 82 KDA antigens from gametocytes of Eimeria maxima and their use
ITMI20011986A1 (it) 2001-09-25 2003-03-25 San Raffaele Centro Fond Metodo e composizione per l'attivazione di cellule presentanti l'antigene
WO2003028441A1 (en) 2001-10-02 2003-04-10 The Board Of Trustees Of The Leland Stanford Junior University Gene therapy for the prevention of autoimmune disease
WO2003051383A2 (de) 2001-12-19 2003-06-26 Alcedo Biotech Gmbh Verwendung von hmgb-proteinen und dafür codierenden nukleinsäuren
DE60227285D1 (de) 2001-12-21 2008-08-07 Immunex Corp Rekombinante polypeptide
JP4304077B2 (ja) 2002-02-13 2009-07-29 イミュノロジー ラボラトリーズ インコーポレイテッド 微生物感染の処置のための組成物および方法
US6923958B2 (en) 2002-03-02 2005-08-02 The Scripps Research Institute DNA vaccines encoding CEA and a CD40 ligand and methods of use thereof
ATE556596T1 (de) 2002-04-15 2012-05-15 Univ St Louis Regulierte attenuierung von lebendimpfstoffen zur verbesserung der kreuzimmunitätsschutzfunktion
US7495090B2 (en) 2002-05-23 2009-02-24 The Regents Of The University Of California Nucleic acids encoding chimeric CD154 polypeptides
CA2505682A1 (en) 2002-11-20 2004-06-03 Kevin J. Tracey Use of hmgb polypeptides for increasing immune responses
US20040156851A1 (en) 2002-11-20 2004-08-12 Critical Therapeutics, Inc. HMGB1 combination therapies
US20040141948A1 (en) 2002-11-20 2004-07-22 Critical Therapeutics, Inc. Use of HMGB fragments as anti-inflammatory agents
AU2003294488B2 (en) 2002-11-20 2007-05-24 Critical Therapeutics, Inc. Use of HMGB fragments as anti-inflammatory agents
US20060014248A1 (en) 2003-01-06 2006-01-19 Xencor, Inc. TNF super family members with altered immunogenicity
US20050181994A1 (en) 2003-01-06 2005-08-18 Xencor, Inc. Novel variants of CD40L protein
US7696169B2 (en) 2003-06-06 2010-04-13 The Feinstein Institute For Medical Research Inhibitors of the interaction between HMGB polypeptides and toll-like receptor 2 as anti-inflammatory agents
US7754209B2 (en) 2003-07-26 2010-07-13 Trubion Pharmaceuticals Binding constructs and methods for use thereof
WO2005025604A2 (en) 2003-09-10 2005-03-24 The General Hospital Corporation Use of hmgb and hmgb fragments to decrease specific immune response
WO2005035570A2 (en) 2003-10-10 2005-04-21 Xencor, Inc. Variants of cd40l protein
US8828957B2 (en) 2003-12-11 2014-09-09 Microvax, Llc Methods for generating immunity to antigen
WO2005058950A2 (en) 2003-12-11 2005-06-30 Sidney Kimmel Cancer Center Methods for generating immunity to antigen
WO2005113598A2 (en) 2004-05-21 2005-12-01 Xencor, Inc. Tnf super family members with altered immunogenicity
US20080305120A1 (en) 2004-06-17 2008-12-11 Medimmune, Inc. Immunogenic Compositions Comprising Hmgb 1 Polypeptides
WO2006012373A2 (en) 2004-07-20 2006-02-02 Critical Therapeutics, Inc. Combination therapies of hmgb and complement inhibitors against inflammation
US20090011426A1 (en) * 2004-08-19 2009-01-08 Mackintosh James A Methods of Diagnosis and Treatment of M.Tuberculosis Infection and Reagents Therefor
DE602005025005D1 (de) 2004-10-07 2011-01-05 Argos Therapeutics Inc Zusammensetzungen reifer dendritischer zellen und verfahren zu deren kultivierung
US8513008B2 (en) 2004-10-07 2013-08-20 Argos Therapeutics, Inc. Mature dendritic cell compositions and methods for culturing same
WO2006105972A1 (en) 2005-04-07 2006-10-12 Universite Libre De Bruxelles Transgenic organism expressing cd40l and uses thereof
US7833979B2 (en) 2005-04-22 2010-11-16 Amgen Inc. Toxin peptide therapeutic agents
WO2006130525A2 (en) 2005-05-31 2006-12-07 Sidney Kimmel Cancer Center Methods for immunotherapy of cancer
EP1909834A2 (en) 2005-07-18 2008-04-16 Critical Therapeutics, Inc. Use of hmgb1 antagonists for the treatment of inflammatory skin conditions
EP1949913B1 (en) 2005-10-07 2010-06-02 Proyecto de Biomedicina Cima, S.L. Immunostimulatory combination for the prophylactics and treatment of hepatitis c
CA2628837C (en) 2005-11-07 2018-11-27 Sidney Kimmel Cancer Center Cd40 ligand fusion protein vaccine
WO2007054658A1 (en) 2005-11-14 2007-05-18 King's College London Control of immune responses
US7829097B2 (en) 2006-02-06 2010-11-09 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Use of HMGB1 for protection against ischemia reperfusion injury
WO2007103048A2 (en) 2006-03-01 2007-09-13 Regents Of The University Of Colorado Tlr agonist (flagellin)/cd40 agonist/antigen protein and dna conjugates and use thereof for inducing synergistic enhancement in immunity
WO2007106073A2 (en) 2006-03-02 2007-09-20 University Of Massachusetts Modified pathogens for use as vaccines
US8604178B2 (en) 2006-09-18 2013-12-10 The Board Of Trustees Of The University Of Arkansas Compositions and methods of enhancing immune responses
US20100292309A1 (en) 2007-03-08 2010-11-18 Mayo Foundation For Medical Education And Research Inducing immune-mediated tumor cell death
CN101024076B (zh) 2007-03-29 2010-08-18 中国农业大学 球虫的新用途
CN102037135A (zh) 2007-10-30 2011-04-27 阿肯色大学评议会 增强对有鞭毛的细菌的免疫反应的组合物和方法
DK2214701T3 (en) 2007-11-01 2016-12-12 Univ Arkansas CONFIGURATIONS AND METHODS FOR IMPROVING THE IMMUNE RESPONSES TO Eimeria
CN101234196A (zh) 2007-11-30 2008-08-06 吉林大学 球虫重组卡介苗及制备方法
US8603766B2 (en) 2008-09-11 2013-12-10 Institut Pasteur Monitoring and inhibiting human immunodeficiency virus infection by modulating HMGB1 dependent triggering of HIV-1 replication and persistence
BRPI0921843B1 (pt) 2008-11-13 2020-11-24 Intervet International B.V. composição de vacina, e, uso de uma composição de vacina
US20100150958A1 (en) 2008-12-15 2010-06-17 Vectogen Pty Ltd. Methods and Compositions for Use of a Coccidiosis Vaccine
JP2011072284A (ja) * 2009-10-01 2011-04-14 Mitsubishi Chemicals Corp 抗体の製造方法及びそれに用いる免疫原性組成物
DK2525817T3 (en) * 2010-01-21 2017-10-02 Univ Arkansas Vaccine vectors and methods for enhancing immune responses
JP5746333B2 (ja) 2010-06-09 2015-07-08 ザ ボード オブ トラスティーズ オブ ザ ユニバーシティ オブ アーカンソー カンピロバクター感染を減少させるワクチン及び方法
MY190866A (en) 2012-10-29 2022-05-13 Univ Arkansas Novel mucosal adjuvants and delivery systems
PT2956165T (pt) 2013-02-14 2019-11-29 Texas A & M Univ Sys Composições e métodos de potenciação das respostas imunitárias frente a eimeria ou limitação de uma infeção por eimeria
US10376571B2 (en) 2013-03-15 2019-08-13 The Board Of Trustees Of The University Of Arkansas Compositions and methods of enhancing immune responses to enteric pathogens

Also Published As

Publication number Publication date
US10328137B2 (en) 2019-06-25
US20180169198A1 (en) 2018-06-21
ES2758759T3 (es) 2020-05-06
US9884099B2 (en) 2018-02-06
JP6874031B2 (ja) 2021-05-19
US20220288175A1 (en) 2022-09-15
DK2956165T3 (da) 2019-12-02
JP2016513956A (ja) 2016-05-19
HK1218880A1 (zh) 2017-03-17
PH12015501784B1 (en) 2015-12-07
EA030929B1 (ru) 2018-10-31
EP3610887C0 (en) 2023-11-15
AU2014216246A8 (en) 2015-11-19
BR112015019283B1 (pt) 2023-12-19
AU2014216246B2 (en) 2018-12-20
US9603915B2 (en) 2017-03-28
US10792351B2 (en) 2020-10-06
JP6532407B2 (ja) 2019-06-19
EP2956165B1 (en) 2019-09-11
MX2015010555A (es) 2015-09-28
US20190298815A1 (en) 2019-10-03
AU2014216246A1 (en) 2015-09-10
EP2956165A4 (en) 2016-09-21
HUE047484T2 (hu) 2020-04-28
PT2956165T (pt) 2019-11-29
CA2900644C (en) 2023-03-14
PH12015501784A1 (en) 2015-12-07
EA201591488A1 (ru) 2016-01-29
MY173328A (en) 2020-01-16
SG10202109925TA (en) 2021-10-28
EP3610887B1 (en) 2023-11-15
EP3610887A1 (en) 2020-02-19
KR102228324B1 (ko) 2021-03-15
BR112015019283A2 (pt) 2017-07-18
NZ711019A (en) 2019-07-26
WO2014127185A1 (en) 2014-08-21
US20160000895A1 (en) 2016-01-07
CN111956796A (zh) 2020-11-20
US11364290B2 (en) 2022-06-21
KR20150119110A (ko) 2015-10-23
SG11201506398SA (en) 2015-09-29
EP3610887B8 (en) 2024-01-24
US20210008184A1 (en) 2021-01-14
US11904005B2 (en) 2024-02-20
CL2015002273A1 (es) 2015-12-04
ES2968398T3 (es) 2024-05-09
ZA201505638B (en) 2023-05-31
JP2019073554A (ja) 2019-05-16
EP2956165A1 (en) 2015-12-23
CA2900644A1 (en) 2014-08-21
AU2014216246A2 (en) 2015-10-01
PL2956165T3 (pl) 2020-04-30
CN105142665A (zh) 2015-12-09
US20170182136A1 (en) 2017-06-29

Similar Documents

Publication Publication Date Title
AR094791A1 (es) Composiciones y métodos para mejorar las respuestas inmunes ante una infección por eimeria o para limitar una infección por eimeria
MX2020004488A (es) Adenovirus y usos de estos.
MX2020004487A (es) Adenovirus y usos de estos.
EA202091039A1 (ru) Аденовирусные векторы и пути их применения
AR105470A1 (es) Métodos para inducir una respuesta inmune
CL2015002741A1 (es) Composiciones y métodos para aumentar la respuesta inmune contra patógenos entéricos
EA201692254A1 (ru) Иммуномодулирующие прогениторные (имп) клетки
BR112017000456A2 (pt) composições antivirais tópicas e métodos de uso das mesmas
CU24405B1 (es) Proteínas de variantes de secuencias de aminoácidos de cry1da1 activas para lepidópteros
CL2019002733A1 (es) Formulaciones de clorhidrato del ácido 1-amino-1-ciclopropanocarboxílico.
PH12015501716B1 (en) Anti-mycoplasma spp. subunit vaccine
CL2016003107A1 (es) Vacunas guiadas por anticuerpos y métodos de uso para generar respuestas inmunitarias maduras rápidas
MX2020004492A (es) Adenovirus y usos de los mismos.
AR089995A1 (es) Vacunas de subunidades de rotavirus, metodos de preparacion y uso de las mismas
CL2015003803A1 (es) Osteopontina lactea de mamifero para mejorar la capacidad de respuesta inmunitaria.
AR103119A1 (es) Uso de elsiglutida para tratar mucositis gastrointestinal, incluyendo diarrea inducida por quimioterapia
CL2018000253A1 (es) Respuesta inmunitaria potenciada de las especies porcinas
MX2019003212A (es) Composiciones que comprenden tensioactivos especificos y altos niveles de glicerina.
CL2018003188A1 (es) Procedimiento para la preparación de cuerpos moldeados para la administración a animales.
ECSP18050673A (es) Formulaciones de giberelina en solución concentrada
CL2018000201A1 (es) Potenciamiento de la respuesta inmunológica en especies acuáticas
IT201600116554A1 (it) Probiotic yeasts as novel vaccination vectors
UY35706A (es) Vacuna contra nematodos de ovinos
PL3645592T3 (pl) Polieteroaminy inicjowane alkoholem tetrahydrofurfurylowym i ich zastosowania
ECSDI15038784S (es) Lentes de realidad virtual con cintas para la cabeza